130 related articles for article (PubMed ID: 4085451)
1. Polyclonal antibodies to quantitate cis-diamminedichloroplatinum(II)--DNA adducts in cancer patients and animal models.
Poirier MC; Reed E; Zwelling LA; Ozols RF; Litterst CL; Yuspa SH
Environ Health Perspect; 1985 Oct; 62():89-94. PubMed ID: 4085451
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
Reed E; Yuspa SH; Zwelling LA; Ozols RF; Poirier MC
J Clin Invest; 1986 Feb; 77(2):545-50. PubMed ID: 3944268
[TBL] [Abstract][Full Text] [Related]
3. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
[TBL] [Abstract][Full Text] [Related]
4. Replication inhibition and translesion synthesis on templates containing site-specifically placed cis-diamminedichloroplatinum(II) DNA adducts.
Comess KM; Burstyn JN; Essigmann JM; Lippard SJ
Biochemistry; 1992 Apr; 31(16):3975-90. PubMed ID: 1314653
[TBL] [Abstract][Full Text] [Related]
5. Antibodies against cisplatin-modified DNA and cisplatin-modified (di)nucleotides.
Terheggen PM; Floot BG; Lempers EL; van Tellingen O; Begg AC; den Engelse L
Cancer Chemother Pharmacol; 1991; 28(3):185-91. PubMed ID: 1855275
[TBL] [Abstract][Full Text] [Related]
6. Immunochemical quantitation of adducts induced in DNA by cis-diamminedichloroplatinum (II) and analysis of adduct-related DNA-unwinding.
Fichtinger-Schepman AM; Baan RA; Luiten-Schuite A; van Dijk M; Lohman PH
Chem Biol Interact; 1985 Nov; 55(3):275-88. PubMed ID: 4075437
[TBL] [Abstract][Full Text] [Related]
7. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
[TBL] [Abstract][Full Text] [Related]
8. Binding of cis- and trans-diamminedichloroplatinum(II) to deoxyribonucleic acid exposes nucleosides as measured immunochemically with anti-nucleoside antibodies.
Sundquist WI; Lippard SJ; Stollar BD
Biochemistry; 1986 Apr; 25(7):1520-4. PubMed ID: 3707890
[TBL] [Abstract][Full Text] [Related]
9. Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
Reed E; Gupta-Burt S; Litterst CL; Poirier MC
Carcinogenesis; 1990 Dec; 11(12):2117-21. PubMed ID: 1979937
[TBL] [Abstract][Full Text] [Related]
10. Antibodies elicited against cis-diamminedichloroplatinum(II)-modified DNA are specific for cis-diamminedichloroplatinum(II)-DNA adducts formed in vivo and in vitro.
Poirier MC; Lippard SJ; Zwelling LA; Ushay HM; Kerrigan D; Thill CC; Santella RM; Grunberger D; Yuspa SH
Proc Natl Acad Sci U S A; 1982 Nov; 79(21):6443-7. PubMed ID: 6959129
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of interaction products of cis-diamminedichloroplatinum(II) and cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) with DNA in cells from platinum-treated cancer patients.
Terheggen PM; Dijkman R; Begg AC; Dubbelman R; Floot BG; Hart AA; den Engelse L
Cancer Res; 1988 Oct; 48(19):5597-603. PubMed ID: 3046743
[TBL] [Abstract][Full Text] [Related]
12. cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats.
Reed E; Litterst CL; Thill CC; Yuspa SH; Poirier MC
Cancer Res; 1987 Feb; 47(3):718-22. PubMed ID: 3802077
[TBL] [Abstract][Full Text] [Related]
13. Differential toxicity of cis- and trans-diamminedichloroplatinum(II) toward mammalian cells: lack of influence of any difference in the rates of loss of their DNA-bound adducts.
Roberts JJ; Friedlos F
Cancer Res; 1987 Jan; 47(1):31-6. PubMed ID: 3791217
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies to DNA modified with cis- or trans-diamminedichloroplatinum(II).
Sundquist WI; Lippard SJ; Stollar BD
Proc Natl Acad Sci U S A; 1987 Dec; 84(23):8225-9. PubMed ID: 2446320
[TBL] [Abstract][Full Text] [Related]
16. Adducts of the antitumor drug cis-diamminedichloroplatinum(II) with DNA: formation, identification, and quantitation.
Fichtinger-Schepman AM; van der Veer JL; den Hartog JH; Lohman PH; Reedijk J
Biochemistry; 1985 Jan; 24(3):707-13. PubMed ID: 4039603
[TBL] [Abstract][Full Text] [Related]
17. Para-aminobenzoic acid suppression of cis-diamminedichloroplatinum(II) nephrotoxicity.
Esposito M; Vannozzi MO; Viale M; Fulco RA; Collecchi P; Merlo F; De Cian F; Zicca A; Cadoni A; Poirier MC
Carcinogenesis; 1993 Dec; 14(12):2595-9. PubMed ID: 8269632
[TBL] [Abstract][Full Text] [Related]
18. DNA adducts of cisplatin and carboplatin in tissues of cancer patients.
Poirier MC; Egorin MJ; Fichtinger-Schepman AM; Yuspa SH; Reed E
IARC Sci Publ; 1988; (89):313-20. PubMed ID: 3058599
[TBL] [Abstract][Full Text] [Related]
19. Platinum-DNA adducts in leukocyte DNA correlate with disease response in ovarian cancer patients receiving platinum-based chemotherapy.
Reed E; Ozols RF; Tarone R; Yuspa SH; Poirier MC
Proc Natl Acad Sci U S A; 1987 Jul; 84(14):5024-8. PubMed ID: 3110781
[TBL] [Abstract][Full Text] [Related]
20. Ultraviolet irradiation produces cytotoxic synergy and increased DNA interstrand crosslinking with cis- and trans-diamminedichloroplatinum(II).
Swinnen LJ; Fisher SG; Erickson LC
Carcinogenesis; 1989 Aug; 10(8):1465-70. PubMed ID: 2752520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
